SELLAS Life Sciences Group Files 8-K
Ticker: SLS · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1390478
| Field | Detail |
|---|---|
| Company | Sellas Life Sciences Group, Inc. (SLS) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
TL;DR
SELLAS Life Sciences Group filed an 8-K on Dec 10, 2024, covering financial statements and exhibits.
AI Summary
On December 10, 2024, SELLAS Life Sciences Group, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Galena Biopharma, Inc. and RXi Pharmaceuticals Corp, is incorporated in Delaware and headquartered in New York.
Why It Matters
This 8-K filing provides updates on the company's financial statements and exhibits, which are crucial for investors to assess the company's financial health and operational status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report detailing financial statements and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- SELLAS Life Sciences Group, Inc. (company) — Registrant
- Galena Biopharma, Inc. (company) — Former Company Name
- RXi Pharmaceuticals Corp (company) — Former Company Name
- December 10, 2024 (date) — Report Date
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and to provide Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on December 10, 2024.
What are the former names of SELLAS Life Sciences Group, Inc.?
The former names of SELLAS Life Sciences Group, Inc. include Galena Biopharma, Inc. and RXi Pharmaceuticals Corp.
In which state is SELLAS Life Sciences Group, Inc. incorporated?
SELLAS Life Sciences Group, Inc. is incorporated in Delaware.
What is the business address of SELLAS Life Sciences Group, Inc.?
The business address of SELLAS Life Sciences Group, Inc. is 7 Times Square, Suite 2503, New York, NY 10036.
Filing Stats: 847 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-12-10 16:45:27
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq St
Filing Documents
- tm2430677d1_8k.htm (8-K) — 29KB
- tm2430677d1_ex99-1.htm (EX-99.1) — 13KB
- tm2430677d1_ex99-2.htm (EX-99.2) — 23KB
- tm2430677d1_ex99-2img01.jpg (GRAPHIC) — 19KB
- tm2430677d1_ex99-2img02.jpg (GRAPHIC) — 10KB
- 0001104659-24-127231.txt ( ) — 288KB
- sls-20241210.xsd (EX-101.SCH) — 3KB
- sls-20241210_lab.xml (EX-101.LAB) — 33KB
- sls-20241210_pre.xml (EX-101.PRE) — 22KB
- tm2430677d1_8k_htm.xml (XML) — 4KB
01
ITEM 7.01 REGULATION FD DISCLOSURE. On December 10, 2024, SELLAS Life Sciences Group, Inc. (the " Company ") issued a press release (the " Press Release ") announcing the triggering of an interim analysis to be conducted by the Independent Data Monitoring Committee (" IDMC ") in its Phase 3 REGAL trial of galinpepimut-S (" GPS ") in acute myeloid leukemia (" AML "). A copy of the Press Release is included as Exhibit 99.1 hereto and is incorporated by reference herein. Additionally, on December 10, 2024, the Company hosted a webcast to review the process leading up to the IDMC meeting and the potential outcomes of the REGAL interim analysis. The webcast is available at https://viavid.webcasts.com/starthere.jsp?ei=1697841&tp_key=5e3028bd5c, and the transcript of the webcast is included as Exhibit 99.2 hereto. The information disclosed under this Item 7.01, including Exhibits 99.1 and 99.2 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing. The Press Release and transcript contain forward-looking "anticipate," "estimate," "plan," "project" and other words of similar import. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and u
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated December 10, 2024. 99.2 SELLAS Life Sciences Group, Inc. Transcript of the Webcast, dated December 10, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SELLAS Life Sciences Group, Inc. Date: December 10, 2024 By: /s/ John T. Burns Name: John T. Burns Title: Senior Vice President, Chief Financial Officer